<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04685096</url>
  </required_header>
  <id_info>
    <org_study_id>19E4487</org_study_id>
    <nct_id>NCT04685096</nct_id>
  </id_info>
  <brief_title>Anti-ageing Efficacy of a Cosmetic Formulation Containing NMN (2%) Versus Placebo</brief_title>
  <official_title>Efficacy Evaluation of the Anti-ageing Effect of a Cosmetic Active Versus Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seneque SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eurofins</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>LGD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seneque SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims at evaluating skin wrinkling, puffiness and fatigue and dark circle appearance&#xD;
      on asian and african-american healthy volunteer cohorts receiving a cosmetic formulation&#xD;
      containing NMN (2%). The product will be evaluated after 28 and 56 days of twice-daily&#xD;
      application in comparison with a reference cosmetic formulation using clinical scoring under&#xD;
      dermatological control. Cosmetic acceptability and future use will also be subjectively&#xD;
      evaluated by analysis of the subjects answers to an evaluation questionnaire.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 12, 2020</start_date>
  <completion_date type="Actual">April 16, 2021</completion_date>
  <primary_completion_date type="Actual">March 12, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Wrinkles</measure>
    <time_frame>Change from baseline (day 0) at days 28 and 56 of application</time_frame>
    <description>clinical grading under dermatological control using 1) a 7 points Visual scale of Bazin from absence (0) to pronounced wrinkles (6) for the Asian panel and 2) a 5 points Visual scale of Bazin from absence (0) to pronounced wrinkles (4) for the Afro-American panel</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Eye bags</measure>
    <time_frame>Change from baseline (day 0) at days 28 and 56 of application</time_frame>
    <description>clinical grading under dermatological control using 1) a 7 points Visual scale of Bazin from absence (0) to pronounced bags (6) for the Asian panel and 2) a 6 points Visual scale of Bazin from absence (0) to pronounced bags (5) for the Afro-American panel</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dark circles</measure>
    <time_frame>Change from baseline (day 0) at days 28 and 56 of application</time_frame>
    <description>clinical grading under dermatological control using 1) a 6 points Visual scale of Dermscan from absence (0) to important dark circles (6) for the Asian panel and 2) a 5 points Visual scale of Dermscan from absence (0) to important dark circles (4) for the Afro-American panel</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relaxed features</measure>
    <time_frame>Change from baseline (day 0) at days 28 and 56 of application</time_frame>
    <description>clinical grading under dermatological control using a 11 points Non structured scale from relaxed features (0) to looking tired (10) for both panels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective evaluation of the product agreeableness and its effects on skin texture, moisture, puffiness, brightness, youth, swelling, wrinkling, radiance and tone.</measure>
    <time_frame>At day 28 of application</time_frame>
    <description>Self-assessment questionnaire on a 5 points scale from &quot;I disagree&quot; (-2) to &quot;I agree&quot; (+2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective evaluation of the product agreeableness and its effects on skin texture, moisture, puffiness, brightness, youth, swelling, wrinkling, radiance and tone.</measure>
    <time_frame>At day 56 of application</time_frame>
    <description>Self-assessment questionnaire on a 5 points scale from &quot;I disagree&quot; (-2) to &quot;I agree&quot; (+2).</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">89</enrollment>
  <condition>Wrinkle</condition>
  <condition>Fatigue</condition>
  <condition>Puffiness Around the Eyes</condition>
  <arm_group>
    <arm_group_label>Asian skin</arm_group_label>
    <description>Twice-daily application for 55 Days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>African-American skin</arm_group_label>
    <description>Twice-daily application for 55 Days</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Test product creme</intervention_name>
    <description>twice daily application of creme containing 2% NMN</description>
    <arm_group_label>African-American skin</arm_group_label>
    <arm_group_label>Asian skin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Reference creme</intervention_name>
    <description>twice daily application of reference creme</description>
    <arm_group_label>African-American skin</arm_group_label>
    <arm_group_label>Asian skin</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Type: Chinese and Afro-American subjects&#xD;
&#xD;
          -  In each group, 50% of the subjects will have normal skin, 50% will have mild dry skin&#xD;
             (declarative)&#xD;
&#xD;
          -  100% will have wrinkles or fine lines on the crow's feet&#xD;
&#xD;
          -  50% will have dark circles (half of them in the Active group, half of them in the&#xD;
             Placebo group)&#xD;
&#xD;
          -  50% will have puffiness (half of them in the Active group, half of them in the&#xD;
             Placebo)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy subject&#xD;
&#xD;
          -  Subject having given her free informed, written consent&#xD;
&#xD;
          -  Subject willing to adhere to the protocol and study procedures&#xD;
&#xD;
          -  Subject with normal frontal temperature lower than 37.5°c/100.4°F&#xD;
&#xD;
          -  Subject has read and understood the information given by the investigator related to&#xD;
             protection against Novel Coronavirus 19 and necessity to contact the investigator in&#xD;
             case of any suspicion of COVID related manifestation (increase of frontal temperature,&#xD;
             cough, sore muscles, weakness…) during the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or nursing woman or woman planning to get pregnant during the study&#xD;
&#xD;
          -  Start, stop or change in hormonal treatment (including contraceptive pill) &lt;1.5 months&#xD;
&#xD;
          -  Cutaneous pathology on the study zone (face)&#xD;
&#xD;
          -  Use of topical or systemic treatment during the previous weeks liable to interfere&#xD;
             with the assessment of the cutaneous efficacy of the study product&#xD;
&#xD;
          -  Subject having undergone a surgery under general anesthesia within the previous month&#xD;
&#xD;
          -  Know allergy to certain cosmetic or dermato-pharmaceutic products&#xD;
&#xD;
          -  Subject having done injections on face and/or a lifting&#xD;
&#xD;
          -  Excessive exposure to sunlight or UV-rays within the month preceding the study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corinne BENIER</last_name>
    <role>Study Director</role>
    <affiliation>Dermscan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eurofins CRL Cosmetics Inc</name>
      <address>
        <city>Piscataway</city>
        <state>New Jersey</state>
        <zip>08854</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eurofins China</name>
      <address>
        <city>Guangzhou</city>
        <zip>510289</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 11, 2020</study_first_submitted>
  <study_first_submitted_qc>December 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2020</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Skin aging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

